Page last updated: 2024-10-18

dalteparin and Epistaxis

dalteparin has been researched along with Epistaxis in 2 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Epistaxis: Bleeding from the nose.

Research Excerpts

ExcerptRelevanceReference
"Surprisingly, the risk for recurrence was similar in the ACAP and control groups (15%, Pā€‰>ā€‰."1.62The Impact of Traditional Anticoagulants, Novel Anticoagulants, and Antiplatelets on Epistaxis. ( Levi, L; Sapir, E; Soudry, E; Yaniv, D; Zavdy, O, 2021)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Yaniv, D1
Zavdy, O1
Sapir, E1
Levi, L1
Soudry, E1
Ahuja, RB1
Bansal, P1
Pradhan, GS1
Subberwal, M1

Trials

1 trial available for dalteparin and Epistaxis

ArticleYear
An analysis of deep vein thrombosis in burn patients (part II): A randomized and controlled study of thrombo-prophylaxis with low molecular weight heparin.
    Burns : journal of the International Society for Burn Injuries, 2016, Volume: 42, Issue:8

    Topics: Adolescent; Adult; Body Surface Area; Burns; Disease Management; Enoxaparin; Epistaxis; Female; Fibr

2016

Other Studies

1 other study available for dalteparin and Epistaxis

ArticleYear
The Impact of Traditional Anticoagulants, Novel Anticoagulants, and Antiplatelets on Epistaxis.
    The Laryngoscope, 2021, Volume: 131, Issue:9

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Case-Control Studies; Enoxapar

2021